Events and Speaking Engagements

SMi’s 3rd Annual ADMET Conference
Organization: SMi Publishing
Location: The Hatton, at etc. venues, London, UK
Date: 2 & 3 July 2008
Topic: Combining In Vitro and In Silico Methods to Avoid Drug Development Mistakes Early
Participants: Katya Tsaioun, Ph.D., Apredica; Pranas Japartas, Pharma Algorithms

Drug Delivery 2008
Organization: Pharmaceutical Education Associates
Location: San Diego, CA
Date: 28-30 July 2008
Topic: Absorption and Toxicity in Intranasal and Lung Delivery
Participants: Katya Tsaioun, Ph.D., Apredica

AAPS Annual Meeting and Exposition
Organization: American Association of Pharmaceutical Scientists
Location: Atlanta, GA
Date: 16-20 November 2008
Program: Exhibition hall

Past Events

Avoiding Hepatotoxic Surprises – An Update on Predictive Tools
Location: 500 Tech Square, Main St, Cambridge, MA
Date: 8:30 – 11:30am. 18 April 2008
Topic: ADDME^sm Avoiding Drug Development Mistakes Early -- Approaching Early Toxicity Assessment as a Business Decision
Participants: Katya Tsaioun, Ph.D., Apredica

Breaking New Ground with Marketing
Location: Odeum Room, Campus Center, Worcester Polytechnic Institute, Worcester, MA
Date: 5:30 - 9:00pm. 8 April 2008
Topic: How to Market to Pharma Companies
Participants: Katya Tsaioun, Ph.D., Apredica

Preclinical Trials: Strategies to Increase Your Chances of Success in Drug Development
Organization: BIOQuébec
Location: Montreal, Québec
Date: 27 March 2008
Topic: Lead Optimization – ADDME^sm: Avoiding Drug Development Mistakes Early
Participants: Katya Tsaioun, Ph.D., Apredica

Predictive Human Toxicity and ADME/Tox Studies
Organization: Mondial Research Group
Location: Brussels, Belgium
Date: 24-25 January 2008
Topic: HERG-450: Combining Assays for Safety Assessment of Drug Candidates
Speaker: Katya Tsaioun, Ph.D., Apredica

"Funding Your Company: How to Finance Your Idea"
Organization: Women Entrepreneurs in Science and Technology
Location: Broad Institute, Cambridge, MA
Date: 29 November 2007, 6:00 pm to 9:00 pm.
Participants: Katya Tsaioun, Ph.D., Apredica; Joanna Horobin, M.D., Syndax Pharmaceuticals; Ania Knap, Ph.D., MaxThera.

"Modern Tools in Drug Discovery and Later-Stage Development ADME-Tox Profiling"
Organization: Massachusetts Biotechnology Council
Location: MBC Office, One Cambridge Center, 9th Floor, Cambridge, MA
Date: 29 November 2007, 8:00 am to 10:00 am.
Participants: Katya Tsaioun, Ph.D., Apredica; Alex Avdeef, Ph.D., pION.

AAPS Annual Meeting and Exposition
Organization: American Association of Pharmaceutical Scientists
Location: San Diego, CA
Date: 11-15 November 2007
Program: Exhibition hall, booth #3532

IBC's Drug Discovery & Development of Innovative Therapeutics Conference
Location: Boston, MA
Date: 6-9 August 2007
Program: Exhibition hall

Seminar: Early Cardiac Toxicity Screening
Location: Cambridge, MA

British Consulate-General
One Memorial Drive, Suite 1500, Cambridge, MA 02142
Directions & Parking       Map

Registration and breakfast: 8:00 - 8:30 am
Seminar: 8:30 - 9:30 am
Discussion and networking: 9:30 - 10:00 am

Safety assessment prior to human clinical trials has become the norm in drug development. It is crucial for reducing attrition in phase 2 and later development, where 75% of failures is now due to safety and metabolism issues. To address this hurdle, the drug discovery and development process is undergoing a paradigm shift. Discovery and development teams are functionally merging so that safety issues are investigated much earlier than ever before.

The most common safety issues are associated with CYP450 and ion channels. CYP450 inhibition can exacerbate interaction with ion channels. A prominent recent example of the consequences of failure to investigate cardiac risk and CYP-3A4 inhibition is the withdrawal of Terfenadine from the market.

This seminar will feature:

• How cardiac safety and other ADME and toxicity issues can be assessed early, quickly, and economically.
• Case studies of drugs withdrawn from the market due to cardiac safety.
• How to use hERG data.
• Literature review on the correlation of human in vivo QT prolongation with available in vitro tests.
• Strategies and techniques for early assessment of cardiac risk.
• Which therapeutic areas and types of drug-discovery programs should be most concerned about cardiac safety.
• Ask the experts your questions about how to address cardiac safety issues in your programs.

Speakers:
Arthur Brown, M.D., ChanTest
Dr. Arthur M. "Buzz" Brown is the founder and CEO of ChanTest, a drug safety testing company specializing in ion channels. He has more than 30 years of experience in ion channel biophysics. His research delineated the pores of voltage-gated and inwardly rectifying potassium channels. At present, his research is on ion channel trafficking with special emphasis on the hERG channel. He holds seven patents concerning ion channels and prevention and treatment of cardiac arrhythmias. He is Adjunct Professor of Physiology and Biophysics, School of Medicine, Case Western Reserve University. Dr. Brown has organized two academic departments at the University of Texas Medical Branch and Baylor College of Medicine and one research institute, the Rammelkamp Center for Education and Research, MetroHealth Campus, Case Western Reserve University.

Katya Tsaioun, Ph.D., Apredica

Bio 2007
Location: MBC Office, One Cambridge Center, 9th Floor, Cambridge, MA
Date: 6-9 May 2007
Program: Exhibition hall - Emerging Companies Pavilion

"Managing Virtual Teams" -- Massachusetts Biotechnology Council
Location: MBC Office, One Cambridge Center, 9th Floor, Cambridge, MA
Date: 19 April 2007
Program: Case study of a collaborative relationship between a small drug-discovery company and contract research teams
Participant: Katya Tsaioun, Ph.D., Apredica

Y50K Biotechnology Entrepreneurial Competition
Location: New Haven, CT
Date: 14 April 2007
Program: Final judging for the Y50K biotechnology business plan competition
Participant: Katya Tsaioun, Ph.D., Apredica, biotech judge

From Discovery to IND
Location: Baltimore, MD
Date: 13-14 March 2007
Topic: A Surer Path to IND: Early ADME-Tox Models for Reducing Downstream Risk of Drug Development
Speakers: Katya Tsaioun, Ph.D., Apredica; Ania Knap, Ph.D., MaxThera

Predictive Human Toxicity and ADME/Tox Studies
Location: Brussels, Belgium
Date: 25-26 January 2007
Topic: Early ADME-Tox Models for Reducing Downstream Risk of Drug Development and Increasing Productivity of Drug Discovery Organizations
Speaker: Katya Tsaioun, Ph.D., Apredica